The Food and Drug Administration approved mFLUSIVA on August 5, the first messenger-RNA flu vaccine cleared for use in the United States, and it cleared over the settled objections of the man who runs the department above it. [1]
Robert F. Kennedy Jr.'s position on the technology is not a fresh reaction to this approval; it is a standing one. He has called mRNA COVID vaccines "the deadliest vaccine ever made" and argued the platform "poses more risks than benefits." [1] We present those as his established framing rather than a dated response to mFLUSIVA, because as of this writing he has not spoken to the specific decision.
Set beside that framing is the process that produced the approval. The FDA's independent advisory panel voted unanimously that the vaccine's benefits outweigh its risks for adults aged 50 to 64, then voted unanimously a second time for adults 65 and older. [1] Two questions, two unanimous panels, one conclusion.
The case for institutional caution is real and worth stating plainly. A regulator's job includes weighing rare harms against broad benefits, demanding long safety records, and refusing novelty for its own sake. A health secretary who insists a new platform clear a high bar is, in the abstract, doing part of that job. The reading breaks only when it collides with the specific verdict the FDA's own scientists already returned, twice, without a single dissent.
The framing carries a price, and the price is not rhetorical. The Department of Health and Human Services has canceled roughly $500 million across 22 mRNA research projects. [1] There is the through-line: the same platform a unanimous panel judged safe and effective for older adults is the platform now losing half a billion dollars in federal development money, on the strength of a position the panel's vote contradicts.
This is the second mRNA milestone our newsroom has covered in a week. What mFLUSIVA is, and the mechanics of the approval, we laid out separately. The pattern is the tension worth watching: the science clears a product at the same moment the department funding the next generation of products pulls back.
